![Tom Boone](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tom Boone
Gründer bei REMD Biotherapeutics, Inc.
Aktive Positionen von Tom Boone
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 | - |
Gründer | 01.01.2011 | - | |
Ally Bridge Group HK Ltd
![]() Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Berater | 01.01.2014 | - |
Karriereverlauf von Tom Boone
Ausbildung von Tom Boone
University of California, Davis | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Hong Kong | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Consultant / Advisor | 1 |
Sektoral
Health Technology | 2 |
Finance | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Health Technology |
Ally Bridge Group HK Ltd
![]() Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Finance |